NDAORALCAPSULEPriority Review
Approved
Apr 2017
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
5/8 — Partial
Priority Review
RYDAPT (rydapt) by Novartis is receptor tyrosine kinase inhibitors [moa]. Approved for kinase inhibitor [epc]. First approved in 2017.
Drug data last refreshed 13h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RYDAPT is an oral receptor tyrosine kinase inhibitor approved in April 2017 for the treatment of systemic mastocytosis and other kinase-driven malignancies. It works by blocking multiple receptor tyrosine kinases that drive cancer cell growth and survival. The drug is currently in peak commercial lifecycle phase.
$31MPart D
Peak4.3 years to LOEMid-size peak-phase asset with modest but stable $31M annual spend and 1,405 claims; brand team likely stabilized with focus on market penetration and indication expansion.
Mechanism of Action
Receptor Tyrosine Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on RYDAPT at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.